KR20240099351A - Gprc5d에 결합하는 항체 및 그 용도 - Google Patents

Gprc5d에 결합하는 항체 및 그 용도 Download PDF

Info

Publication number
KR20240099351A
KR20240099351A KR1020247017404A KR20247017404A KR20240099351A KR 20240099351 A KR20240099351 A KR 20240099351A KR 1020247017404 A KR1020247017404 A KR 1020247017404A KR 20247017404 A KR20247017404 A KR 20247017404A KR 20240099351 A KR20240099351 A KR 20240099351A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
variable region
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017404A
Other languages
English (en)
Korean (ko)
Inventor
젠젠 루
유지에 왕
슈앙리 펭
젱핑 장
Original Assignee
치아타이 티안큉 파마수티컬 그룹 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치아타이 티안큉 파마수티컬 그룹 주식회사 filed Critical 치아타이 티안큉 파마수티컬 그룹 주식회사
Publication of KR20240099351A publication Critical patent/KR20240099351A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247017404A 2021-11-05 2022-11-04 Gprc5d에 결합하는 항체 및 그 용도 Pending KR20240099351A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111305149 2021-11-05
CN202111305149.7 2021-11-05
PCT/CN2022/129803 WO2023078382A1 (zh) 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途

Publications (1)

Publication Number Publication Date
KR20240099351A true KR20240099351A (ko) 2024-06-28

Family

ID=86240662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017404A Pending KR20240099351A (ko) 2021-11-05 2022-11-04 Gprc5d에 결합하는 항체 및 그 용도

Country Status (6)

Country Link
EP (1) EP4428153A4 (https=)
JP (1) JP2024540148A (https=)
KR (1) KR20240099351A (https=)
CN (1) CN118159565A (https=)
TW (1) TW202334222A (https=)
WO (1) WO2023078382A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925229B (zh) * 2023-09-19 2023-12-15 南京驯鹿生物技术股份有限公司 一种靶向gprc5d的抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
US12545726B1 (en) 2025-07-22 2026-02-10 Integral Molecular, Inc. Compositions and methods related to GPRC5D binding agents and variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017011932A8 (pt) * 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
SG11201907321TA (en) * 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d

Also Published As

Publication number Publication date
WO2023078382A1 (zh) 2023-05-11
EP4428153A4 (en) 2026-02-11
EP4428153A1 (en) 2024-09-11
TW202334222A (zh) 2023-09-01
JP2024540148A (ja) 2024-10-31
CN118159565A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
EP4428153A1 (en) Antibody binding to gprc5d and use thereof
JP7604379B2 (ja) 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途
US20250145705A1 (en) Gprc5d antibody and application thereof
US20240309087A1 (en) Anti-cd112r antibody and use thereof
KR20230132544A (ko) 신규한 항-그렘린1 항체
KR20250017233A (ko) 항-bdca2 항체 및 이의 용도
AU2024225804A1 (en) Antibodies, antigen-binding fragments and methods of use
CN109721656A (zh) 靶向rankl的治疗性抗体
KR20250084976A (ko) 항cd16a 항체 및 이의 적용
IL324067A (en) Bispecific antibody targeting g protein-coupled receptor
WO2024094017A1 (zh) 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
CN117586402A (zh) NKp80抗体及其应用
CN117964772A (zh) NKp80-CD155双特异性抗体及其应用
CN118556082A (zh) p95HER2抗体及其应用
WO2023178645A1 (zh) 靶向cd3的抗体及其应用
EP4585618A1 (en) Anti-ilt4 antibody and pharmaceutical use thereof
RU2807484C2 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и его фармацевтическое применение
JP2026506623A (ja) 抗ｃｄｈ６抗体及びその使用
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr
AU2024331841A1 (en) Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
JP2026513553A (ja) 抗ｂｄｃａ２抗体
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
CN118894943A (zh) 靶向密蛋白的双特异性抗体
CN120842400A (zh) 泌乳素受体抗体及其用途
CN118894944A (zh) 抗密蛋白双特异性抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000